Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004571|
Recruitment Status : Recruiting
First Posted : February 16, 2000
Last Update Posted : June 7, 2021
The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers.
Schizophrenia is a brain disorder that results from subtle changes and abnormalities in neurons. These deficits likely occur in localized regions of the brain and may result in widespread, devastating consequences. The neuronal abnormalities are inherited through a complex combination of genetic and environmental factors. Brain imaging technologies can be used to better characterize brain changes in individuals with schizophrenia. This study will use magnetic resonance imaging (MRI) scans to identify predictable, quantifiable abnormalities in neurophysiology, neurochemistry and neuroanatomy that characterize schizophrenia and other neurological and neuropsychiatric disorders.
|Condition or disease|
|Schizophrenia Normal Physiology|
This protocol is meant to provide a matrix for multiple, simultaneous brain imaging investigations using magnetic resonance imaging (MRI) at 3.0 Tesla (3T). We intend to study regional brain structure, physiology, and biochemistry in living human subjects, both healthy and ill. Based on multiple clinical, neuropathological, and functional neuroimaging studies, it is clear that schizophrenia is a brain disorder arising from subtle neuronal deficits (for lack of more specific terminology). These deficits likely arise in a few key regions such as dorsolateral prefrontal cortex and hippocampal formation, that result in widespread, multifaceted, and devastating clinical consequences. These neuronal deficits are clearly heritable, although in a complex fashion from multiple genes interacting in an epistatic fashion with each other and the environment. We hypothesize that these neuronal deficits, clearly resulting in quantifiable behavioral abnormalities in schizophrenic patients, will produce predictable, quantifiable aberrations in neurophysiology that we can "map" using magnetic resonance imaging. In spite of numerous functional imaging findings, clinical applications remain scarce and pathognomic findings absent. Therefore, we do not anticipate that an approach based solely on any one modality is likely to significantly advance our knowledge base. Instead, we propose to create brain imaging datasets for individual human subjects predicated on 1) the appraisal of brain function from multiple domains simultaneously; 2) the characterization of brain function via summation and intercorrelation of these data; and 3) the digestion of these data based on the parsing of complex clinical phenomenology into quantifiable neurophysiological parameters. Thus, in addition to the identification of those parameters that best characterize and identify manifest schizophrenia (i.e., state variables), we hypothesize that some of these fundamental characteristics will be heritable. These fundamental characteristics, so-called endo- or intermediate phenotypes, represent powerful tools to find susceptibility genes and have already generated a number of linkage findings.
Precis of Substudy: Effects of prosocial neuropeptides on human brain function
The goal of this substudy is to delineate neural systems involved in fear processing, emotional memory, and cognition reactive to intranasally applied prosocial neuropeptides (oxytocin, vasopressin) as a prelude to defining genetic variation in humans impacting on this circuit.
|Study Type :||Observational|
|Estimated Enrollment :||2920 participants|
|Official Title:||Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 3.0 Tesla MRI and Magnetoencephalography|
|Actual Study Start Date :||February 17, 2000|
Healthy subjects from the community
Patients with schizophrenia and psychosis
Individuals with copy number variation in the Williams Syndrome Region.
- fMRI BOLD responses [ Time Frame: MRI study completion ]Group differences between patients with schizophrenia and healthy subjects, also genotyping used to characterize subjects as well.
- magnetic field potentials [ Time Frame: MEG ]Group differences in MEG signal for patients with schizophrenia and healthy subjects.
- DTI anisotropy measures [ Time Frame: DTI ]Compare fractional anisotropy and other measures of white matterconnectivity for schizophrenic patients and controls.
- brain volumetric measures [ Time Frame: VBM ]VBM and cortical parcellation are used in schizophrenia and healthy controls.
- regional MRSI measures [ Time Frame: spectroscopy ]GABA and glutamate measurements in schizophrenia and healthycontrols.
- neuropsychological task performance data
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004571
|Contact: Bobby Das||(301) firstname.lastname@example.org|
|Contact: Karen F Berman, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: Bobby Das, M.S. 301-435-4593 firstname.lastname@example.org|
|Principal Investigator:||Karen F Berman, M.D.||National Institute of Mental Health (NIMH)|